SOMERVILLE, Mass.--(BUSINESS WIRE)--Generate:Biomedicines today announced a publication in Nature describing Chroma, a generative AI model that can program novel proteins not previously found in nature with targeted biophysical, biological, and therapeutic properties. Along with this announcement, the company is making the model available to the broader research community with the goal of accelerating scientific progress in generative biology.

马萨诸塞州萨默维尔-（商业信息）-生成：Biomedicines今天宣布在Nature上发表一篇描述Chroma的出版物，Chroma是一种生成性AI模型，可以编程以前在自然界中未发现的具有靶向生物物理，生物和治疗特性的新型蛋白质。随着本公告的发布，该公司正在将该模型提供给更广泛的研究界，目的是加速生成生物学的科学进步。

The code behind Chroma is available as open-source software and the model weights are freely accessible to academic researchers and non-profit entities..

Chroma背后的代码可作为开源软件使用，学术研究人员和非营利实体可免费访问模型权重。。

“What is exciting about this result is that we have demonstrated that fundamentally new ‘molecular concepts’ can now be generated at will and used to create novel proteins with a diverse set of desired properties,” said Gevorg Grigoryan, Co-Founder and Chief Technology Officer of Generate:Biomedicines.

“这一结果令人兴奋的是，我们已经证明，现在可以随意生成基本上新的”分子概念”，并用于创建具有多种所需特性的新型蛋白质，”Gevorg Grigoryan，联合创始人兼首席技术官说。GENATE：生物医学。

“By making the code open source, we’re proud to share this breakthrough in generative biology with the world to help advance our shared goals of fundamentally changing the way protein therapies are created.”.

“通过使代码开源，我们很自豪与世界分享生殖生物学的这一突破，以帮助推进我们从根本上改变蛋白质疗法创造方式的共同目标。”。

While protein-based therapeutics are a substantial part of the pharmaceutical market, nearly all existing treatment approaches focus on modifying proteins found in nature – which represent only a small fraction of all possible proteins. Through its Chroma model, Generate:Biomedicines can now harness the power of generative AI to infer generalizable principles governing the relationships among protein sequence, structure, and function.

虽然基于蛋白质的疗法是制药市场的重要组成部分，但几乎所有现有的治疗方法都侧重于修饰自然界中发现的蛋白质-这些蛋白质仅占所有可能蛋白质的一小部分。通过其Chroma模型，生成：生物医学现在可以利用生成AI的力量来推断控制蛋白质序列，结构和功能之间关系的一般化原则。

In doing so, the company can quickly design novel protein molecules with a wide range of therapeutic properties, realizing the potential for generative AI where protein design developments happen much faster than previously possible – with significant impact on health, materials science, and other areas..

通过这样做，该公司可以快速设计具有广泛治疗特性的新型蛋白质分子，实现生成AI的潜力，其中蛋白质设计开发的发生速度比以前快得多-对健康，材料科学和其他领域产生重大影响。。

“Nature’s publication of our Chroma model sends an unequivocal message to the broader scientific community that biology is becoming programmable,” said Mike Nally, Chief Executive Officer of Generate:Biomedicines. “By combining machine learning with world-class wet lab capabilities, we are uniquely positioned to continue developing medicines that can treat and cure humanity’s most intractable diseases, all while establishing and sustaining our competitive advantage in AI-enabled drug discovery and development.”.

“自然出版我们的Chroma模型向更广泛的科学界发出了一个明确的信息，即生物学正在变得可编程，”Generate:Biomedicines首席执行官Mike Nally说。“通过将机器学习与世界级湿实验室能力相结合，我们处于独特的地位，继续开发可以治疗和治疗人类最难治的疾病的药物，同时建立和维持我们在AI药物发现和开发方面的竞争优势。”。

To learn more about the Chroma model, download the open-source package, or read the open access publication in Nature, visit generatebiomedicines.com/chroma.

要了解有关Chroma模型的更多信息，请下载开源软件包或阅读Nature中的开放获取出版物，请访问generatebiomedicines.com/Chroma。

About Generative Biology

关于生成生物学

Generative biology represents a fundamental shift in therapeutic development driven by generative artificial intelligence (AI). This approach creates never-before-seen therapeutic molecules targeted to specific biological processes involved in disease that can be modulated with a wide range of protein modalities—from short peptides to complex antibodies, enzymes, and cytokines.

生成生物学代表了由生成人工智能（AI）驱动的治疗发展的根本转变。这种方法创造了前所未有的针对疾病中涉及的特定生物过程的治疗性分子，其可以用从短肽到复杂抗体，酶和细胞因子的各种蛋白质形式进行调节。

But the promise of generative biology goes beyond existing proteins found in nature and can create novel proteins that are purpose-built to address an existing or emerging therapeutic need. As a result, generative biology promises to leave trial-and-error drug discovery methods behind to usher in a new era of programmable drug generation that’s faster, cheaper, and better tailored to specific conditions..

但是，生成生物学的前景超越了自然界中存在的现有蛋白质，并且可以创造旨在解决现有或新兴治疗需求的新型蛋白质。因此，生成生物学有望留下反复试验的药物发现方法，开创一个更快，更便宜，更适合特定条件的可编程药物生成新时代。。

About Generate:Biomedicines

关于生成：生物医学

Generate:Biomedicines is the first drug generation company pioneering a machine learning-powered generative biology platform with the ability to create new drugs on demand across a wide range of biologic modalities. The Generate Platform – which is a continuous loop to generate, build, measure, and learn – can drastically increase the speed at which targets and therapeutics are identified and validated.

生成：Biomedicines是第一家开创机器学习动力生成生物学平台的药物生成公司，能够在各种生物模式下按需创建新药。生成平台是生成，构建，测量和学习的连续循环，可以大大提高识别和验证目标和治疗方法的速度。

This will improve the specificity of target engagement by generated proteins and reduce the time and cost of identifying and developing clinical candidates. Generate:Biomedicines is a clinical stage company that was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020.

这将提高产生的蛋白质对靶标参与的特异性，并减少鉴定和开发临床候选物的时间和成本。Generate:Biomedicines是一家临床阶段公司，由Flagship开拓公司在其实验室部门进行了两年的基础研究，并于2020年启动。

Learn more about Generate:Biomedicines by visiting https://​gen​er​ate​bio​med​i​cines​.com/ or following the company on Twitter and LinkedIn..

了解更多关于Generate：生物医学通过访问https：//​消息​呃​吃了​生物​医学​我​电影​.com/或关注Twitter和LinkedIn上的公司。。